News articles about China Cord Blood (NYSE:CO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. China Cord Blood earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.0517664636992 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

China Cord Blood (NYSE:CO) opened at $10.02 on Friday. The company has a market capitalization of $1,208.45, a price-to-earnings ratio of 28.63 and a beta of 0.88. China Cord Blood has a 1 year low of $4.27 and a 1 year high of $14.95.

COPYRIGHT VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/17/china-cord-blood-co-given-daily-news-impact-rating-of-0-12.html.

China Cord Blood Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood (NYSE:CO)

Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.